You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ):今年公司還計劃上市鴨瘟重組H5活疫苗,以及噬菌體、救必應提取物散等幾款中獸藥
格隆匯 04-26 15:35

格隆匯4月26日丨瑞普生物(300119.SZ)於2024年04月25日召開業績説明會,就“請問公司近兩年將在家禽板塊有哪些大單品推出?”,公司回覆稱,公司在家禽板塊聚焦多聯多價疫苗、原創藥物製劑、中獸藥產品等,近日公司收到雞新城疫、禽流感(H9亞型)、禽腺病毒(Ⅰ羣,4型)三聯滅活疫苗(LaSota株+TJ-4株+RP-8-C株)三類新獸藥證書,爭取今年推向市場。此外,今年公司還計劃上市鴨瘟重組H5活疫苗,以及噬菌體、救必應提取物散等幾款中獸藥。

未來兩年,公司將陸續推出禽用鹽酸沃尼妙林晶體可溶性粉、新流法腺四聯滅活疫苗、鼻炎三價亞單位疫苗、新支二聯活疫苗(VII+QX)等產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account